EUVIMEDEUVIMED entdecken
Crossref

Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data

Emilio Albamonte, Adrea Lizio, Giorgia Coratti, Lorenzo Maggi, Elena Pegoraro, Marika Pane, Sonia Messina, Riccardo Masson, Adele D'Amico, Enrico Bertini, Antonella Pini, Federica Ricci und 14 weitere

Neurological Sciences · 2025

DOI: 10.1007/s10072-025-08125-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurological Sciences, 2025. Verfasst von Emilio Albamonte und 25 weiteren Autor:innen. Beteiligte Einrichtung: The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy. emilio.albamonte@centrocliniconemo.it. Hauptthemen laut MEDLINE: Oligonucleotides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: (i) provide a snapshot from a large cohort of Italian patients with SMA on risdiplam in the real-world setting; (ii) identify any differences in the cohorts before and after commercial drug approval considering the different eligibility access criteria (iii) describe preliminary data on adherence to treatment and reasons for shifting from nusinersen to risdiplam. METHODS: Charts from patients on risdiplam were retrospectively reviewed. Results were then compared between patients accessing the drug during an initial restricted compassionate use program (cohort 1) and those after commercial approval, with no restrictions (cohort 2). Side effects and adherence were recorded for both cohorts as well as data on shifters. RESULTS: 283 patients (median age: 22 years) were included. Only a minority were walkers. Respiratory and bulbar comorbidities were more severe in cohort 1 (58% non sitters) than in cohort 2 (52% sitters). 35% and 46% of patients from cohorts 1 and 2 shifted from nusinersen to risdiplam respectively. Adherence and safety profile were good in both cohorts. CONCLUSIONS: This is the largest cohort described so far providing insights on the characteristics of patients on risdiplam in the real world. The disability level and age were very different from those that had driven efficacy results in the trials. This may at least in part produce some evidence to account for the variable results reported so far in the realworld. Importantly, the safety profile was confirmed even in these more severely disabled and older patients compared to those in the trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesHumansItalyMaleFemaleRetrospective StudiesYoung AdultAdultAdolescentChildChild, PreschoolCohort StudiesMiddle AgedInfant

Stichwörter der Autor:innen

AdherenceCompassionate use programRisdiplamSafetySpinal Muscular Atrophy

Substanzen

Oligonucleotidesnusinersen

Autor:innen und Institutionen

  • The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy. emilio.albamonte@centrocliniconemo.it.
  • The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, Milan, Italy.
  • Pediatric Neuromuscular Unit, The NEMO Center in Rome, Rome, Italy.
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Neuroimmunology and Neuromuscular Disease Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Department of Neurosciences, University of Padova, Padua, Italy.

Zitieren

APA

Albamonte, E., Lizio, A., Coratti, G., Maggi, L., Pegoraro, E., Pane, M., Messina, S., Masson, R., D'Amico, A., Bertini, E., Pini, A., Ricci, F., Mongini, T., Bruno, C., Patanella, K., Sframeli, M., Dosi, C., Bonanno, S., Scarpini, G., …, & ItaSMAc (2025). Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data. Neurological Sciences. https://doi.org/10.1007/s10072-025-08125-7

Vancouver

Albamonte E, Lizio A, Coratti G, Maggi L, Pegoraro E, Pane M, et al. Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data. Neurological Sciences. 2025. doi:10.1007/s10072-025-08125-7

BibTeX
@article{Albamonte2025,
  author = {Albamonte, Emilio and Lizio, Adrea and Coratti, Giorgia and Maggi, Lorenzo and Pegoraro, Elena and Pane, Marika and Messina, Sonia and Masson, Riccardo and D'Amico, Adele and Bertini, Enrico and Pini, Antonella and Ricci, Federica and Mongini, Tiziana and Bruno, Claudio and Patanella, Katia and Sframeli, Maria and Dosi, Claudia and Bonanno, Silvia and Scarpini, Gaia and Brolatti, Noemi and Zanolini, Alice and Bravetti, Chiara and Pera, Maria Carmela and Mercuri, Eugenio Maria and Sansone, Valeria Ada and ItaSMAc, ItaSMAc},
  title = {Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data},
  journal = {Neurological Sciences},
  year = {2025},
  doi = {10.1007/s10072-025-08125-7}
}
Kostenlos starten →